Citations

Clear

479 citation(s) found for "Tobias, JS".

Antifibrotics Modify B-Cell–Induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis
Ali, Mohamed F. , Egan, Ashley M. , Shaughnessy, Gaja F., Anderson, Dagny K., Dasari, Harika , Keulen, Virginia P. Van , Aubry, Marie‐Christine, Yi, Eunhee S. , Peikert, Tobias, Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J. , Aubry, Marie-Christine, Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | March 9, 2021 | Volume: 64 | Issue: 6 | Pages: 722-733

10.1165/rcmb.2020-0387oc | PMID 33689587 Get It

Abstract B-cell activation is increasingly linked to numerous fibrotic lung diseases, and it is well known that aggregates of lymphocytes form in the lung of many of these patients. Activation of B-cells by pattern recognition receptors (PRRs) drives the release of inflammatory cytokines, chemokines, and metalloproteases important in the pathophysiology of pulmonary fibrosis. However, the specific mechanisms of B-cell activation in patients with idiopathic pulmonary fibrosis (IPF) are poorly understood. Herein, we have demonstrated that B-cell activation by microbial antigens contributes to the inflammatory and profibrotic milieu seen in patients with IPF. B-cell stimulation by CpG and β-glucan via PRRs resulted in activation of mTOR-dependent and independent pathways. Moreover, we showed that the B-cell–secreted inflammatory milieu is specific to the inducing antigen and causes differential fibroblast migration and activation. B-cell responses to infectious agents and subsequent B-cell–mediated fibroblast activation are modifiable by antifibrotics, but each seems to exert a specific and different effect. These results suggest that, upon PRR activation by microbial antigens, B-cells can contribute to the inflammatory and fibrotic changes seen in patients with IPF, and antifibrotics are able to at least partially reverse these responses.
Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative
Dirven, Linda , Vos, Maartje E, Walbert, Tobias , Arons, David, Bent, Martin J. van den , Brown, Paul D. , Chang, Susan M. , Coens, Corneel , Grant, Robin, Jalali, Rakesh , Leach, Danielle, Mendoza, Tito R. , Nayak, Lakshmi , Oliver, Kathy , Reijneveld, Jaap C. , Wen, Patrick Y. , Taphoorn, Martin , Mendoza, Tito , Weller, Michael , van den Bent, Martin J , Armstrong, Terri S. , Blakeley, Jaishri O. , Bulbeck, Helen , Gilbert, Mark R. , Leeper, Heather , Rhun, Émilie Le , Rubinstein, Larry , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology Practice | February 14, 2021 | Volume: 8 | Issue: 4 | Pages: 417-425

10.1093/nop/npab013 | PMID 34277020 Get It

Abstract Background The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high quality, both in terms of relevance and other measurement properties. This systematic review aimed to identify PRO measures that have been used in brain tumor studies to date. Methods A systematic literature search for articles published up to June 25, 2020 was conducted in several electronic databases. Pre-specified inclusion criteria were used to identify studies using PRO measures assessing symptoms, (instrumental) activities of daily living [(I)ADL] or health-related quality of life (HRQoL) in adult patients with glioma, meningioma, primary central nervous system lymphoma, or brain metastasis. Results A total of 215 different PRO measures were identified in 571 published and 194 unpublished studies. The identified PRO measures include brain tumor-specific, cancer-specific, and generic instruments, as well as instruments designed for other indications or multi- or single-item study-specific questionnaires. The most frequently used instruments were the EORTC QLQ-C30 and QLQ-BN20 (n = 286 and n = 247), and the FACT-Br (n = 167), however, the majority of the instruments were used only once or twice (150/215). Conclusion Many different PRO measures assessing symptoms, (I)ADL or HRQoL have been used in brain tumor studies to date. Future research should clarify whether these instruments or their scales/items exhibit good content validity and other measurement properties for use in brain tumor patients.
Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics
Chen, Po‐Chia , Xu, Emma-Ruoqi , Tischer, Alexander , Klemm, Ulrike, Meß, Christian , Obser, Tobias, Kutzki, Fabian, König, Gesa, Denis, Cécile V. , Wilmanns, Matthias , Schneider, Stefan W. , Schneppenheim, Reinhard , Hennig, Janosch , Brehm, Maria A. , Auton, Matthew , Xu, Emma-Ruoqi , Wilmanns, Matthias , Tischer, Alexander , Huck, Volker , Aponte-Santamaria, Camilo A. , Gräter, Frauke

Mayo Clinic

Thrombosis and Haemostasis | January 1, 2021 | Volume: 122 | Issue: 02 | Pages: 226-239

10.1055/a-1344-4405 | PMID 33385180 Get It

AbstractThe multimeric plasma glycoprotein (GP) von Willebrand factor (VWF) is best known for recruiting platelets to sites of injury during primary hemostasis. Generally, mutations in the VWF gene lead to loss of hemostatic activity and thus the bleeding disorder von Willebrand disease. By employing cone and platelet aggregometry and microfluidic assays, we uncovered a platelet GPIIb/IIIa-dependent prothrombotic gain of function (GOF) for variant p.Pro2555Arg, located in the C4 domain, leading to an increase in platelet aggregate size. We performed complementary biophysical and structural investigations using circular dichroism spectra, small-angle X-ray scattering, nuclear magnetic resonance spectroscopy, molecular dynamics simulations on the single C4 domain, and dimeric wild-type and p.Pro2555Arg constructs. C4-p.Pro2555Arg retained the overall structural conformation with minor populations of alternative conformations exhibiting increased hinge flexibility and slow conformational exchange. The dimeric protein becomes disordered and more flexible. Our data suggest that the GOF does not affect the binding affinity of the C4 domain for GPIIb/IIIa. Instead, the increased VWF dimer flexibility enhances temporal accessibility of platelet-binding sites. Using an interdisciplinary approach, we revealed that p.Pro2555Arg is the first VWF variant, which increases platelet aggregate size and shows a shear-dependent function of the VWF stem region, which can become hyperactive through mutations. Prothrombotic GOF variants of VWF are a novel concept of a VWF-associated pathomechanism of thromboembolic events, which is of general interest to vascular health but not yet considered in diagnostics. Thus, awareness should be raised for the risk they pose. Furthermore, our data implicate the C4 domain as a novel antithrombotic drug target.
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis
Speidl, Walter S. , Jaffe, Allan S. , Mair, Johannes , Möckel, Martin , Mueller, Christian, Storey, Robert F. , Vilahur, Gemma , Huber, Kurt , Halvorsen, Sigrun , Geisler, Tobias , Morais, João , Thygesen, Kristian , Storey, Robert F , Huber, Kurt , Thygesen, Kristian , Mockel, Martin , Krychtiuk, Konstantin A , Giannitsis, Evangelos , Gigante, Bruna , Gorog, Diana Adrienne , Jaffe, Allan S. , Wojta, Johann , Lindahl, Bertil

Mayo Clinic

European Heart Journal Acute Cardiovascular Care | December 31, 2020 | Volume: 10 | Issue: 3 | Pages: 343-355

10.1093/ehjacc/zuaa025 | PMID 33620437 Get It

Abstract The formation of a thrombus in an epicardial artery may result in an acute myocardial infarction (AMI). Despite major advances in acute treatment using network approaches to allocate patients to timely reperfusion and optimal antithrombotic treatment, patients remain at high risk for thrombotic complications. Ongoing activation of the coagulation system as well as thrombin-mediated platelet activation may both play a crucial role in this context. Whether measurement of circulating biomarkers of coagulation and fibrinolysis could be useful for risk stratification in secondary prevention is currently not fully understood. In addition, measurement of such biomarkers could be helpful to identify thrombus formation as the leading mechanism for AMI. The introduction of biomarkers of myocardial injury such as high-sensitivity cardiac troponins made rule-out of AMI even more precise. However, elevated markers of myocardial injury cannot provide proof of a type 1 AMI, let alone thrombus formation. The combined measurement of markers of myocardial injury with biomarkers reflecting ongoing thrombus formation might be helpful for the fast and correct diagnosis of an atherothrombotic type 1 AMI. This position paper gives an overview of the current knowledge and possible role of biomarkers of coagulation and fibrinolysis for the diagnosis of AMI, risk stratification, and individualized treatment strategies in patients with AMI.
Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease
Yang, David Y. , Köhler, Tobias , Trost, Landon , Ziegelmann, Matthew , Yang, David, Helo, Sevann , Yang Md, David , Savage, Joshua S.

Mayo Clinic

Sexual Medicine | December 8, 2020 | Volume: 9 | Issue: 1 | Pages: 100282-100282

10.1016/j.esxm.2020.10.010 | PMID 33307341 Get It

Abstract Peyronie's disease (PD) is associated with significant psychosocial distress, including anxiety, depression, and negative effects on interpersonal relationships. We report outcomes in a patient who researched an enzymatic supplement intended for oral administration for treatment of PD and subsequently self-injected it intravascularly. The enzyme, a combination of serrapeptase and nattokinase, resulted in vascular necrosis of the upper extremity. Despite attempts to salvage the limb, he ultimately required transhumeral amputation. Although extreme, this case illustrates the potential risks of non–Food and Drug Administration–approved therapies, the significant psychosocial impact that PD can have on patients' emotional well-being, and the extent to which some may go to seek treatment. Yang D, Savage J, Kohler T, et al. Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease. Sex Med 2021;9:100282.
The Impact of Surgical Strategy and Rifampin on Treatment Outcome in Cutibacterium Periprosthetic Joint Infections
Kusejko, Katharina , Auñón, Álvaro , Jost, Bernhard , Natividad, Benito, Strahm, Carol , Thurnheer, Christine, Pablo‐Marcos, Daniel , Slama, Dorsaf, Scanferla, Giulia, Waldmann, Isabelle, Esteban, Jaime , Lora-Tamayo, Jaime, Clauss, Martin , Fernández-Sampedro, Marta , Wouthuyzen‐Bakker, Marjan , Ferrari, Matteo Carlo , Gassmann, Natalie, Sendi, Parham , Jent, Philipp , Morand, P , Vijayvargiya, Prakhar , Patel, Robin , Kouyos, Roger D. , Kramer, Tobias Siegfried , Patel, Robin , Sendi, Parham , Wouthuyzen-Bakker, Marjan , Benito, Natividad , Uçkay, İlker , Gassmann, Natalie, Morand, Philippe C, Trebše, Rihard , Corvec, Stéphane , Stadelmann, Vincent A. , Achermann, Yvonne

Mayo Clinic

Clinical Infectious Diseases | December 8, 2020 | Volume: 72 | Issue: 12 | Pages: e1064-e1073

10.1093/cid/ciaa1839 | PMID 33300545 Get It

Abstract Background Cutibacterium species are common pathogens in periprosthetic joint infections (PJI). These infections are often treated with β-lactams or clindamycin as monotherapy, or in combination with rifampin. Clinical evidence supporting the value of adding rifampin for treatment of Cutibacterium PJI is lacking. Methods In this multicenter retrospective study, we evaluated patients with Cutibacterium PJI and a minimal follow-up of 12 months. The primary endpoint was clinical success, defined by the absence of infection relapse or new infection. We used Fisher’s exact tests and Cox proportional hazards models to analyze the effect of rifampin and other factors on clinical success after PJI. Results We included 187 patients (72.2% male, median age 67 years) with a median follow-up of 36 months. The surgical intervention was a 2-stage exchange in 95 (50.8%), 1-stage exchange in 51 (27.3%), debridement and implant retention (DAIR) in 34 (18.2%), and explantation without reimplantation in 7 (3.7%) patients. Rifampin was included in the antibiotic regimen in 81 (43.3%) cases. Infection relapse occurred in 28 (15.0%), and new infection in 13 (7.0%) cases. In the time-to-event analysis, DAIR (adjusted hazard ratio [HR] = 2.15, P = .03) and antibiotic treatment over 6 weeks (adjusted HR = 0.29, P = .0002) significantly influenced treatment failure. We observed a tentative evidence for a beneficial effect of adding rifampin to the antibiotic treatment—though not statistically significant for treatment failure (adjusted HR = 0.5, P = .07) and not for relapses (adjusted HR = 0.5, P = .10). Conclusions We conclude that a rifampin combination is not markedly superior in Cutibacterium PJI, but a dedicated prospective multicenter study is needed.
Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
Blennow, Kaj , Machado, Alejandra , Lindberg, Olof , Zettergren, Anna , Skillbäck, Tobias Borgh , Zetterberg, Henrik , Shams, Sara , Pereira, Joana B. , Mielke, Michelle M. , Rydén, Lina , Westman, Eric , Wahlund, Lars‐Olof , Skoog, Ingmar , Kern, Silke

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.038588 Get It

AbstractBackgroundCSF neurofilament light protein (NfL) is an important biomarker in several neurologic diseases. CSF NfL concentrations are known to increase with age, but sex differences have been less examined. The CSF/serum albumin ratio (QAlb) is a biomarker for blood‐brain barrier integrity, which has previously been found to be higher in men. As NfL and QAlb are used in clinical routine, the impact of demographic factors on these biomarkers is important to understand.MethodParticipants were derived from two samples. The first was a population‐based cohort of 308 70‐year olds from the Gothenburg H70 Birth Cohort Study, Sweden. The second data set comprised CSF NfL and QAlb results from 8995 and 39252 subjects respectively, generated in clinical practice between 2005‐2012 in Gothenburg, Sweden. In the population‐based study, QAlb and NfL concentrations were examined in relation to sex, cardiovascular risk factors, and MRI signs of cerebral white matter lesions. In the clinical routine cohort, sex differences in QAlb and NfL were tested in relation to age.ResultIn the population‐based sample, men had higher QAlb and NfL concentrations than women. NfL was not related to cerebral vascular pathology, but QAlb correlated positively with several measures of white matter lesions. In the clinical routine cohort, men also had higher QAlb and NfL concentrations from adolescence and throughout life.ConclusionQAlb ratios and CSF NfL levels are higher in men throughout life. The CSF NfL sex difference could not be explained by vascular pathology. Future studies should consider using different reference limits for men and women.
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
Ford, Janet H. , Kurth, Tobias , Starling, Amaal J. , Ayer, David W. , Wietecha, Linda, Port, Martha , Rettiganti, Mallikarjuna, Ruff, Dustin, Port, Martha D , Kurth, Tobias

Mayo Clinic

Headache: The Journal of Head and Face Pain | November 29, 2020 | Volume: 60 | Issue: 10 | Pages: 2304-2319

10.1111/head.14013 | PMID 33249580 Get It

Objective This post hoc study investigated the relationship between patient response in terms of migraine headache day reduction and patient‐reported outcomes of health‐related quality of life (HRQoL) and disability categories. Background Migraine causes considerable disease‐related disability and negatively impacts HRQoL of patients. Calcitonin gene‐related peptide inhibitors improve these outcomes and may eliminate disability due to migraine in some patients. Methods Analyses used data from 3 double‐blind, placebo (PBO)‐controlled, phase 3 studies in adults with episodic migraine (EM) (EVOLVE‐1: N = 858 and EVOLVE‐2: N = 915) or chronic migraine (CM) (REGAIN: N = 1113). Patients were randomized 2:1:1 to subcutaneous injection of PBO, galcanezumab (GMB) 120 mg, or GMB 240 mg once monthly for 6 months in EVOLVE‐1 and ‐2 and for 3 months in REGAIN. Primary endpoint was overall mean change from baseline in monthly migraine headache days. Patients were divided into 4 response‐level groups based on percent change from baseline (<30%, ≥30% to <50%, ≥50% to <75%, ≥75%). Patient‐reported outcomes included the 14‐item Migraine‐Specific Quality of Life Questionnaire version 2.1 (MSQ) and Migraine Disability Assessment (MIDAS) questionnaire. Results Among patients with migraine, mean improvements from baseline in MSQ domain scores increased with each successive level of migraine headache day response. On a 100‐pt scale, increases in Role Function‐Restrictive score in EM were 16.8 and 36.0 at the <30% and ≥75% response levels, respectively, and for CM were 10.7 and 46.5. Similar patterns in scores were observed for the Role Function‐Preventive and Emotional Function domains. Examination of improvement in MSQ item score by treatment group showed that, in patients with EM, approximately 10 to 20% more GMB‐treated patients (N = 796 for GMB 120 mg and GMB 240 mg) had improvements in all 14 MSQ items compared with PBO‐treated patients (N = 773) (all P < .001). In patients with CM, 3 to 16% more GMB‐treated patients (N = 507) had improvements in the 14 MSQ items compared with PBO (N = 494), though differences were statistically significant in only 19 of 28 comparisons. At baseline, mean MIDAS scores (EM, 33.1; CM, 67.2) indicated severe mean disability for patients with EM and very severe disability for patients with CM. Among patients with EM, 215 of 425 (50.6%) of those treated with GMB 120 mg and 212 of 413 (51.3%) treated with 240 mg had little/no disability due to migraine after 6 months (PBO: 277 of 832 (33.3%), P < .001 for both). Among patients with CM, 50 of 254 (19.7%) of those treated with GMB 120 mg and 54 of 258 (20.9%) treated with 240 mg reached the level of little/no disability after 3 months of treatment (PBO: 70 of 504 (13.9%), P = .045 for 120 mg, P = .017 for 240 mg). Conclusions Because migraine greatly impairs an individual’s ability to participate in activities of daily living, measurements of HRQoL are essential in clinical research. This study showed that function in daily life, as measured by MSQ score, improved as migraine headache days were reduced and that GMB‐treated patients were more likely to see improvement in MSQ item scores compared with PBO‐treated patients. Elimination of migraine‐related disability was also more frequent in GMB‐treated patients compared with placebo‐treated patients.
Outcomes of RestoreX Penile Traction Therapy in Men with Peyronie’s Disease: Results from Open Label and Follow-Up Phases
Ziegelmann, Matthew , Alom, Manaf, Köhler, Tobias , Trost, Landon , Joseph, Jason , Ziegelmann, Matthew J, Savage, Joshua, Savage, Joshua S.

Mayo Clinic

The Journal of Sexual Medicine | November 20, 2020 | Volume: 17 | Issue: 12 | Pages: 2462-2471

10.1016/j.jsxm.2020.10.003 | PMID 33223425 Get It

Abstract Background A randomized, controlled clinical trial evaluating the efficacy of RestoreX traction therapy in men with Peyronie’s disease (PD) has been completed, with the 3-month results previously reported. The present study presents outcomes from the open-label and follow-up phases of the original trial. Aim To report 6-month (open-label phase) and 9-month (follow-up phase) outcomes from a randomized, controlled trial (NCT03389854). Methods A randomized controlled trial was performed from 2017 to 2019 in 110 all-comer men with PD. Men were randomized 3:1 to RestoreX (PTT) or no therapy (control) for 3 months, followed by 3-month open-label and follow-up phases. Key outcomes included adverse events (AEs), changes in penile curvature and length, erectile function, and standardized and nonstandardized assessments of PD. Outcomes The primary outcomes are safety, penile length, penile curvature, Peyronie’s Disease Questionnaire, International Index of Erectile Function, and satisfaction. Results 6-month (n = 64) and 9-month (n = 63) outcomes were reported, with a mean duration of PTT use of 31.1 minutes. No significant AEs were reported, with temporary erythema and discomfort being most common and resolving within minutes. On intent-to-treat analysis, control-to-PTT men experienced significant length (1.7–2.0 cm) and curvature improvements (18–20%). PTT-to-PTT men also achieved additional length (0.6–0.8 cm) without further curvature improvements. An as-treated analysis of PTT use ≥15 minute/day demonstrated 2.0- to 2.3-cm length gains (largest of any PTT to date) and 18–21% curve improvement. All sexual function domains of the International Index of Erectile Function and Peyronie’s Disease Questionnaire were significantly improved (except orgasmic domain). 95% of men treated for 6 months experienced length gains (mean 2.0–2.2 cm), and 61% had curve improvements (16.8–21.4° [32.8–35.8%]). RestoreX was preferred 3–4:1 over all other PD treatments, and 100% preferred it over other PTT devices. Clinical Implications Use of RestoreX 30 minutes daily results in significant length and curve improvements in PD men without significant AEs. Strengths & Limitations Strengths include largest randomized study of PTT, blinded assessments, and inclusion of all-comers with few restrictions; limitations include sample size that precludes comparisons between treatment cohorts and lack of long-duration (&gt;3–9 hours) treatment arm. Conclusion PTT with RestoreX results in significant improvements in length, curve, and subjective and objective measures of sexual function without significant AEs. RestoreX PTT represents a safe, conservative, low-cost option for managing men with PD.
Ruptured Ectopic Pregnancy with an Intrauterine Device: Case Report and Sonographic Considerations
Jones, Derick D. , Kummer, Tobias , Schoen, Jessica C. , Jones, Derick

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | November 17, 2020 | Volume: 4 | Issue: 4 | Pages: 559-563

10.5811/cpcem.2020.7.48258 | PMID 33217272 Get It

Introduction: Ectopic pregnancy carries a high morbidity and mortality; patients are at risk for rupture and life-threatening hemorrhage. Case Report: We present a rare case of ruptured abdominal ectopic pregnancy in a patient with a well-positioned intrauterine device (IUD) and discuss the diagnostic utility that transabdominal point-of-care ultrasound (POCUS) can have when performed at the bedside. Conclusion: While pregnancy with an IUD in place is rare, when it is encountered the emergency provider should maintain a high degree of suspicion for extrauterine pregnancy and perform prompt evaluation for hemorrhagic shock using diagnostic POCUS.